O	0	5	Phase	Phase	NN	B-NP
O	6	8	II	II	CD	I-NP
O	9	14	trial	trial	NN	I-NP
O	15	19	with	with	IN	B-PP
O	20	21	D	D	NN	B-NP
O	21	22	-	-	HYPH	B-NP
O	22	25	Trp	Trp	NN	I-NP
O	25	26	-	-	HYPH	B-NP
O	26	27	6	6	CD	I-NP
O	27	28	-	-	HYPH	I-NP
O	28	30	LH	LH	NN	I-NP
O	30	31	-	-	HYPH	I-NP
O	31	33	RH	RH	NN	I-NP
O	34	36	in	in	IN	B-PP
B-Cancer	37	46	prostatic	prostatic	JJ	B-NP
I-Cancer	47	56	carcinoma	carcinoma	NN	I-NP
O	56	57	:	:	:	O
O	58	68	comparison	comparison	NN	B-NP
O	69	73	with	with	IN	B-PP
O	74	79	other	other	JJ	B-NP
O	80	88	hormonal	hormonal	JJ	I-NP
O	89	95	agents	agent	NNS	I-NP
O	95	96	.	.	.	O

O	97	104	Various	Various	JJ	B-NP
O	105	115	approaches	approach	NNS	I-NP
O	116	118	to	to	TO	B-PP
O	119	127	hormonal	hormonal	JJ	B-NP
O	128	137	treatment	treatment	NN	I-NP
O	138	140	of	of	IN	B-PP
B-Cancer	141	149	prostate	prostate	NN	B-NP
I-Cancer	150	159	carcinoma	carcinoma	NN	I-NP
O	160	163	are	be	VBP	B-VP
O	164	173	discussed	discuss	VBN	I-VP
O	173	174	.	.	.	O

O	175	181	Eighty	Eighty	CD	B-NP
O	181	182	-	-	HYPH	I-NP
O	182	185	one	one	CD	B-NP
O	186	194	patients	patient	NNS	I-NP
O	195	199	with	with	IN	B-PP
B-Cancer	200	209	prostatic	prostatic	JJ	B-NP
I-Cancer	210	219	carcinoma	carcinoma	NN	I-NP
O	219	220	,	,	,	O
O	221	226	eight	eight	CD	B-NP
O	227	231	with	with	IN	B-PP
O	232	237	stage	stage	NN	B-NP
O	238	239	B	B	NN	I-NP
O	239	240	,	,	,	O
O	241	245	nine	nine	CD	B-NP
O	246	250	with	with	IN	B-PP
O	251	256	stage	stage	NN	B-NP
O	257	258	C	C	NN	I-NP
O	258	259	,	,	,	O
O	260	263	and	and	CC	O
O	264	266	64	64	CD	B-NP
O	267	271	with	with	IN	B-PP
O	272	277	stage	stage	NN	B-NP
O	278	279	D	D	NN	I-NP
O	280	287	disease	disease	NN	I-NP
O	287	288	,	,	,	O
O	289	293	were	be	VBD	B-VP
O	294	301	treated	treat	VBN	I-VP
B-Immaterial_anatomical_entity	302	316	subcutaneously	subcutaneously	RB	B-ADVP
O	317	322	daily	daily	RB	I-ADVP
O	323	326	for	for	IN	B-PP
O	327	328	3	3	CD	B-NP
O	329	335	months	month	NNS	I-NP
O	336	340	with	with	IN	B-PP
O	341	344	the	the	DT	B-NP
O	345	347	LH	LH	NN	I-NP
O	347	348	-	-	HYPH	B-NP
O	348	350	RH	RH	NN	I-NP
O	351	358	agonist	agonist	NN	I-NP
O	359	360	D	D	NN	I-NP
O	360	361	-	-	HYPH	B-NP
O	361	364	Trp	Trp	NN	I-NP
O	364	365	-	-	HYPH	B-NP
O	365	366	6	6	CD	I-NP
O	366	367	-	-	HYPH	I-NP
O	367	369	LH	LH	NN	I-NP
O	369	370	-	-	HYPH	I-NP
O	370	372	RH	RH	NN	B-NP
O	373	374	(	(	(	O
O	374	384	Decapeptyl	Decapeptyl	NN	B-NP
O	384	385	)	)	)	O
O	386	388	in	in	IN	B-SBAR
O	389	394	order	order	NN	O
O	395	397	to	to	TO	B-VP
O	398	406	evaluate	evaluate	VB	I-VP
O	407	410	the	the	DT	B-NP
O	411	420	incidence	incidence	NN	I-NP
O	421	423	of	of	IN	B-PP
O	424	434	remissions	remission	NNS	B-NP
O	435	444	according	accord	VBG	B-PP
O	445	447	to	to	TO	B-PP
O	448	451	WHO	WHO	NN	B-NP
O	452	467	recommendations	recommendation	NNS	I-NP
O	468	471	for	for	IN	B-PP
O	472	481	oncologic	oncologic	JJ	B-NP
O	482	488	trials	trial	NNS	I-NP
O	488	489	.	.	.	O

O	490	493	The	The	DT	B-NP
O	494	502	findings	finding	NNS	I-NP
O	503	507	were	be	VBD	B-VP
O	508	516	compared	compare	VBN	I-VP
O	517	519	to	to	TO	B-PP
O	520	525	those	those	DT	B-NP
O	526	534	obtained	obtain	VBN	B-VP
O	535	539	with	with	IN	B-PP
O	540	545	other	other	JJ	B-NP
O	546	554	hormonal	hormonal	JJ	I-NP
O	555	564	therapies	therapy	NNS	I-NP
O	565	567	of	of	IN	B-PP
B-Cancer	568	577	prostatic	prostatic	JJ	B-NP
I-Cancer	578	587	carcinoma	carcinoma	NN	I-NP
O	588	597	according	accord	VBG	B-PP
O	598	600	to	to	TO	B-PP
O	601	604	the	the	DT	B-NP
O	605	616	statistical	statistical	JJ	I-NP
O	617	623	method	method	NN	I-NP
O	624	626	of	of	IN	B-PP
O	627	628	"	"	``	O
O	628	636	expected	expected	JJ	B-NP
O	637	645	response	response	NN	I-NP
O	646	650	rate	rate	NN	I-NP
O	650	651	"	"	''	O
O	652	654	as	as	IN	B-SBAR
O	655	662	adapted	adapt	VBN	B-VP
O	663	665	by	by	IN	B-PP
O	666	669	Lee	Lee	NNP	B-NP
O	670	673	and	and	CC	I-NP
O	674	680	Wesley	Wesley	NNP	I-NP
O	681	684	for	for	IN	B-PP
O	685	690	phase	phase	NN	B-NP
O	691	693	II	II	CD	I-NP
O	694	700	trials	trial	NNS	I-NP
O	700	701	.	.	.	O

O	702	711	Treatment	Treatment	NN	B-NP
O	712	716	with	with	IN	B-PP
O	717	718	D	D	NN	B-NP
O	718	719	-	-	HYPH	B-NP
O	719	722	Trp	Trp	NN	I-NP
O	722	723	-	-	HYPH	B-NP
O	723	724	6	6	CD	I-NP
O	724	725	-	-	HYPH	I-NP
O	725	727	LH	LH	NN	I-NP
O	727	728	-	-	HYPH	I-NP
O	728	730	RH	RH	NN	I-NP
O	731	738	greatly	greatly	RB	B-ADVP
O	739	746	reduced	reduce	VBD	B-VP
B-Organism_substance	747	752	serum	serum	NN	B-NP
O	753	755	LH	LH	NN	I-NP
O	756	759	and	and	CC	I-NP
O	760	772	testosterone	testosterone	NN	I-NP
O	773	779	levels	level	NNS	I-NP
O	780	787	without	without	IN	B-PP
O	788	795	raising	raise	VBG	B-VP
B-Organism_substance	796	801	serum	serum	NN	B-NP
O	802	811	prolactin	prolactin	NN	I-NP
O	811	812	.	.	.	O

O	813	818	After	After	IN	B-PP
O	819	820	1	1	CD	B-NP
O	820	821	-	-	HYPH	I-NP
O	821	822	2	2	CD	I-NP
O	823	828	weeks	week	NNS	I-NP
O	829	831	of	of	IN	B-PP
O	832	839	therapy	therapy	NN	B-NP
O	839	840	,	,	,	O
O	841	846	there	there	EX	B-NP
O	847	850	was	be	VBD	B-VP
O	851	857	relief	relief	NN	B-NP
O	858	860	of	of	IN	B-PP
O	861	871	subjective	subjective	JJ	B-NP
O	872	880	symptoms	symptom	NNS	I-NP
O	881	884	and	and	CC	O
O	885	886	a	a	DT	B-NP
O	887	895	reversal	reversal	NN	I-NP
O	896	898	of	of	IN	B-PP
O	899	902	the	the	DT	B-NP
O	903	908	signs	sign	NNS	I-NP
O	909	911	of	of	IN	B-PP
O	912	922	prostatism	prostatism	NN	B-NP
O	923	925	as	as	RB	B-CONJP
O	926	930	well	well	RB	I-CONJP
O	931	933	as	as	IN	I-CONJP
O	934	935	a	a	DT	B-NP
O	936	942	marked	marked	JJ	I-NP
O	943	951	decrease	decrease	NN	I-NP
O	952	954	in	in	IN	B-PP
B-Organ	955	959	bone	bone	NN	B-NP
O	960	964	pain	pain	NN	I-NP
O	964	965	.	.	.	O

O	966	968	At	At	IN	B-PP
O	969	971	90	90	CD	B-NP
O	972	976	days	day	NNS	I-NP
O	977	979	52	52	CD	B-NP
O	980	988	patients	patient	NNS	I-NP
O	989	992	had	have	VBD	B-VP
O	993	1001	complete	complete	JJ	B-NP
O	1002	1008	relief	relief	NN	I-NP
O	1009	1011	of	of	IN	B-PP
O	1012	1022	prostatism	prostatism	NN	B-NP
O	1023	1026	and	and	CC	O
O	1027	1029	21	21	CD	B-NP
O	1030	1033	had	have	VBD	B-VP
O	1034	1038	only	only	RB	B-NP
O	1039	1043	mild	mild	JJ	I-NP
O	1044	1049	signs	sign	NNS	I-NP
O	1050	1053	and	and	CC	I-NP
O	1054	1062	symptoms	symptom	NNS	I-NP
O	1062	1063	.	.	.	O

O	1064	1071	Seventy	Seventy	CD	B-NP
O	1072	1080	patients	patient	NNS	I-NP
O	1081	1085	were	be	VBD	B-VP
O	1086	1098	experiencing	experience	VBG	I-VP
O	1099	1101	no	no	DT	B-NP
B-Organ	1102	1106	bone	bone	NN	I-NP
O	1107	1111	pain	pain	NN	I-NP
O	1112	1115	and	and	CC	O
O	1116	1118	an	an	DT	B-NP
O	1119	1129	additional	additional	JJ	I-NP
O	1130	1133	six	six	CD	I-NP
O	1134	1137	had	have	VBD	B-VP
O	1138	1142	only	only	RB	B-NP
O	1143	1147	mild	mild	JJ	I-NP
O	1148	1152	pain	pain	NN	I-NP
O	1152	1153	.	.	.	O

B-Organ	1154	1163	Prostatic	Prostatic	JJ	B-NP
O	1164	1168	size	size	NN	I-NP
O	1168	1169	,	,	,	O
O	1170	1179	evaluated	evaluate	VBN	B-VP
O	1180	1182	by	by	IN	B-PP
O	1183	1189	rectal	rectal	JJ	B-NP
O	1190	1201	examination	examination	NN	I-NP
O	1202	1205	and	and	CC	O
B-Organism_subdivision	1206	1220	transabdominal	transabdominal	JJ	B-NP
O	1221	1236	ultrasonography	ultrasonography	NN	I-NP
O	1236	1237	,	,	,	O
O	1238	1246	reverted	revert	VBD	B-VP
O	1247	1249	to	to	TO	B-PP
O	1250	1256	normal	normal	JJ	B-NP
O	1257	1259	in	in	IN	B-PP
O	1260	1262	26	26	CD	B-NP
O	1262	1263	.	.	.	O
O	1263	1264	4	4	CD	B-NP
O	1264	1265	%	%	NN	I-NP
O	1266	1268	of	of	IN	B-PP
O	1269	1277	patients	patient	NNS	B-NP
O	1278	1279	(	(	(	O
O	1279	1287	complete	complete	JJ	B-NP
O	1288	1297	remission	remission	NN	I-NP
O	1297	1298	)	)	)	O
O	1299	1302	and	and	CC	O
O	1303	1306	was	be	VBD	B-VP
O	1307	1314	reduced	reduce	VBN	I-VP
O	1315	1317	by	by	IN	B-PP
O	1318	1322	more	more	JJR	B-NP
O	1323	1327	than	than	IN	I-NP
O	1328	1330	50	50	CD	I-NP
O	1330	1331	%	%	NN	I-NP
O	1332	1334	in	in	IN	B-PP
O	1335	1337	an	an	DT	B-NP
O	1338	1348	additional	additional	JJ	I-NP
O	1349	1351	17	17	CD	I-NP
O	1351	1352	.	.	.	I-NP
O	1352	1353	6	6	CD	I-NP
O	1353	1354	%	%	NN	I-NP
O	1355	1356	(	(	(	O
O	1356	1363	partial	partial	JJ	B-NP
O	1364	1373	remission	remission	NN	I-NP
O	1373	1374	)	)	)	O
O	1374	1375	,	,	,	O
O	1376	1379	the	the	DT	B-NP
O	1380	1387	overall	overall	JJ	I-NP
O	1388	1392	rate	rate	NN	I-NP
O	1393	1395	of	of	IN	B-PP
O	1396	1404	complete	complete	JJ	B-NP
O	1405	1409	plus	plus	CC	I-NP
O	1410	1417	partial	partial	JJ	I-NP
O	1418	1428	regression	regression	NN	I-NP
O	1429	1431	of	of	IN	B-PP
B-Organ	1432	1441	prostatic	prostatic	JJ	B-NP
O	1442	1453	enlargement	enlargement	NN	I-NP
O	1454	1459	being	be	VBG	B-VP
O	1460	1462	44	44	CD	B-NP
O	1462	1463	%	%	NN	I-NP
O	1463	1464	.	.	.	O

O	1465	1470	Scans	Scan	NNS	B-NP
O	1471	1477	showed	show	VBD	B-VP
O	1478	1479	a	a	DT	B-NP
O	1480	1485	major	major	JJ	I-NP
O	1486	1497	improvement	improvement	NN	I-NP
O	1498	1500	of	of	IN	B-PP
B-Cancer	1501	1505	bone	bone	NN	B-NP
I-Cancer	1506	1513	lesions	lesion	NNS	I-NP
O	1514	1516	in	in	IN	B-PP
O	1517	1519	14	14	CD	B-NP
O	1519	1520	.	.	.	O
O	1520	1521	8	8	CD	B-NP
O	1521	1522	%	%	NN	I-NP
O	1523	1525	of	of	IN	B-PP
O	1526	1531	cases	case	NNS	B-NP
O	1531	1532	.	.	.	O

O	1533	1537	This	This	DT	B-NP
O	1538	1546	response	response	NN	I-NP
O	1547	1556	increased	increase	VBD	B-VP
O	1557	1559	to	to	TO	B-PP
O	1560	1562	37	37	CD	B-NP
O	1562	1563	%	%	NN	I-NP
O	1564	1569	after	after	IN	B-PP
O	1570	1574	more	more	JJR	B-NP
O	1575	1579	than	than	IN	I-NP
O	1580	1581	6	6	CD	I-NP
O	1582	1588	months	month	NNS	I-NP
O	1589	1591	of	of	IN	B-PP
O	1592	1598	follow	follow	VB	B-VP
O	1598	1599	-	-	HYPH	O
O	1599	1601	up	up	RP	B-PRT
O	1601	1602	.	.	.	O

B-Organ	1603	1612	Prostatic	Prostatic	JJ	B-NP
O	1613	1617	acid	acid	NN	I-NP
O	1618	1629	phosphatase	phosphatase	NN	I-NP
O	1630	1636	levels	level	NNS	I-NP
O	1637	1641	were	be	VBD	B-VP
O	1642	1651	decreased	decrease	VBN	I-VP
O	1652	1654	by	by	IN	B-PP
O	1655	1659	more	more	JJR	B-NP
O	1660	1664	than	than	IN	I-NP
O	1665	1667	50	50	CD	I-NP
O	1667	1668	%	%	NN	I-NP
O	1669	1671	in	in	IN	B-PP
O	1672	1674	61	61	CD	B-NP
O	1674	1675	%	%	NN	I-NP
O	1676	1678	of	of	IN	B-PP
O	1679	1682	the	the	DT	B-NP
O	1683	1691	patients	patient	NNS	I-NP
O	1691	1692	,	,	,	O
O	1693	1696	but	but	CC	O
O	1697	1701	this	this	DT	B-NP
O	1702	1706	test	test	NN	I-NP
O	1707	1714	appears	appear	VBZ	B-VP
O	1715	1717	to	to	TO	I-VP
O	1718	1720	be	be	VB	I-VP
O	1721	1722	a	a	DT	B-NP
O	1723	1727	less	less	RBR	I-NP
O	1728	1733	valid	valid	JJ	I-NP
O	1734	1740	marker	marker	NN	I-NP
O	1741	1745	than	than	IN	B-PP
O	1746	1749	the	the	DT	B-NP
O	1750	1755	lipid	lipid	NN	I-NP
O	1755	1756	-	-	HYPH	O
O	1756	1766	associated	associate	VBN	B-VP
O	1767	1773	sialic	sialic	JJ	B-NP
O	1774	1778	acid	acid	NN	I-NP
O	1779	1780	(	(	(	O
O	1780	1784	LASA	LASA	NN	B-NP
O	1784	1785	)	)	)	O
O	1785	1786	.	.	.	O

O	1787	1790	The	The	DT	B-NP
O	1791	1799	increase	increase	NN	I-NP
O	1800	1802	in	in	IN	B-PP
O	1803	1807	LASA	LASA	NN	B-NP
O	1808	1814	before	before	IN	B-PP
O	1815	1824	treatment	treatment	NN	B-NP
O	1825	1828	and	and	CC	O
O	1829	1830	a	a	DT	B-NP
O	1831	1840	reduction	reduction	NN	I-NP
O	1841	1846	after	after	IN	B-PP
O	1847	1856	treatment	treatment	NN	B-NP
O	1857	1860	can	can	MD	B-VP
O	1861	1871	frequently	frequently	RB	I-VP
O	1872	1874	be	be	VB	I-VP
O	1875	1885	correlated	correlate	VBN	I-VP
O	1886	1890	with	with	IN	B-PP
O	1891	1894	the	the	DT	B-NP
O	1895	1904	objective	objective	JJ	I-NP
O	1905	1911	volume	volume	NN	I-NP
O	1912	1914	of	of	IN	B-PP
O	1915	1918	the	the	DT	B-NP
B-Cancer	1919	1928	neoplasms	neoplasm	NNS	I-NP
O	1928	1929	.	.	.	O

O	1930	1932	No	No	DT	B-NP
O	1933	1938	flare	flare	VB	B-VP
O	1938	1939	-	-	HYPH	O
O	1939	1941	up	up	RP	B-PRT
O	1942	1944	of	of	IN	B-PP
O	1945	1948	the	the	DT	B-NP
O	1949	1956	disease	disease	NN	I-NP
O	1957	1960	was	be	VBD	B-VP
O	1961	1972	encountered	encounter	VBN	I-VP
O	1972	1973	,	,	,	O
O	1974	1977	and	and	CC	O
O	1978	1983	there	there	EX	B-NP
O	1984	1988	were	be	VBD	B-VP
O	1989	1991	no	no	DT	B-NP
O	1992	1996	side	side	JJ	I-NP
O	1997	2004	effects	effect	NNS	I-NP
O	2005	2011	except	except	IN	B-PP
O	2012	2015	for	for	IN	B-PP
O	2016	2025	impotence	impotence	NN	B-NP
O	2025	2026	.	.	.	O

O	2027	2038	Statistical	Statistical	JJ	B-NP
O	2039	2047	analyses	analysis	NNS	I-NP
O	2048	2050	of	of	IN	B-PP
O	2051	2058	results	result	NNS	B-NP
O	2059	2061	by	by	IN	B-PP
O	2062	2065	the	the	DT	B-NP
O	2066	2072	method	method	NN	I-NP
O	2073	2075	of	of	IN	B-PP
O	2076	2079	Lee	Lee	NNP	B-NP
O	2080	2083	and	and	CC	I-NP
O	2084	2090	Wesley	Wesley	NNP	I-NP
O	2091	2100	indicated	indicate	VBD	B-VP
O	2101	2105	that	that	IN	B-SBAR
O	2106	2109	the	the	DT	B-NP
O	2110	2119	incidence	incidence	NN	I-NP
O	2120	2122	of	of	IN	B-PP
O	2123	2131	complete	complete	JJ	B-NP
O	2132	2135	and	and	CC	I-NP
O	2136	2143	partial	partial	JJ	I-NP
O	2144	2154	regression	regression	NN	I-NP
O	2155	2156	(	(	(	O
O	2156	2158	CR	CR	NN	B-NP
O	2159	2162	and	and	CC	O
O	2163	2165	PR	PR	NN	B-NP
O	2165	2166	)	)	)	O
O	2167	2175	observed	observe	VBN	B-VP
O	2176	2180	with	with	IN	B-PP
O	2181	2182	D	D	NN	B-NP
O	2182	2183	-	-	HYPH	B-NP
O	2183	2186	Trp	Trp	NN	I-NP
O	2186	2187	-	-	HYPH	B-NP
O	2187	2188	6	6	CD	I-NP
O	2188	2189	-	-	HYPH	I-NP
O	2189	2191	LH	LH	NN	I-NP
O	2191	2192	-	-	HYPH	I-NP
O	2192	2194	RH	RH	NN	I-NP
O	2195	2198	was	be	VBD	B-VP
O	2199	2202	not	not	RB	O
O	2203	2216	significantly	significantly	RB	B-ADJP
O	2217	2226	different	different	JJ	I-ADJP
O	2227	2231	from	from	IN	B-PP
O	2232	2236	that	that	DT	B-NP
O	2237	2245	recorded	record	VBN	B-VP
O	2246	2248	in	in	IN	B-PP
O	2249	2257	previous	previous	JJ	B-NP
O	2258	2265	studies	study	NNS	I-NP
O	2266	2269	for	for	IN	B-PP
O	2270	2277	another	another	DT	B-NP
O	2278	2280	LH	LH	NN	I-NP
O	2280	2281	-	-	HYPH	B-NP
O	2281	2283	RH	RH	NN	I-NP
O	2284	2290	analog	analog	NN	I-NP
O	2290	2291	,	,	,	O
O	2292	2301	Buserelin	Buserelin	NN	B-NP
O	2301	2302	.	.	.	O

O	2303	2310	However	However	RB	B-ADVP
O	2310	2311	,	,	,	O
O	2312	2314	CR	CR	NN	B-NP
O	2315	2318	and	and	CC	I-NP
O	2319	2321	PR	PR	NN	I-NP
O	2322	2330	obtained	obtain	VBN	B-VP
O	2331	2335	with	with	IN	B-PP
O	2336	2337	D	D	NN	B-NP
O	2337	2338	-	-	HYPH	B-NP
O	2338	2341	Trp	Trp	NN	I-NP
O	2341	2342	-	-	HYPH	B-NP
O	2342	2343	6	6	CD	I-NP
O	2343	2344	-	-	HYPH	I-NP
O	2344	2346	LH	LH	NN	I-NP
O	2346	2347	-	-	HYPH	I-NP
O	2347	2349	RH	RH	NN	I-NP
O	2350	2351	(	(	(	O
O	2351	2353	44	44	CD	B-NP
O	2353	2354	%	%	NN	I-NP
O	2354	2355	)	)	)	O
O	2356	2360	were	be	VBD	B-VP
O	2361	2374	significantly	significantly	RB	B-ADJP
O	2375	2381	higher	high	JJR	I-ADJP
O	2382	2386	than	than	IN	B-PP
O	2387	2391	with	with	IN	B-PP
O	2392	2403	subcapsular	subcapsular	JJ	B-NP
O	2404	2415	orchiectomy	orchiectomy	NN	I-NP
O	2416	2417	(	(	(	O
O	2417	2419	22	22	CD	B-NP
O	2419	2420	%	%	NN	I-NP
O	2420	2421	)	)	)	O
O	2421	2422	.	.	.	O

O	2423	2431	Hormonal	Hormonal	JJ	B-NP
O	2432	2439	effects	effect	NNS	I-NP
O	2440	2443	and	and	CC	O
O	2444	2448	some	some	DT	B-NP
O	2449	2454	other	other	JJ	I-NP
O	2455	2462	actions	action	NNS	I-NP
O	2463	2465	of	of	IN	B-PP
O	2466	2467	D	D	NN	B-NP
O	2467	2468	-	-	HYPH	B-NP
O	2468	2471	Trp	Trp	NN	I-NP
O	2471	2472	-	-	HYPH	B-NP
O	2472	2473	6	6	CD	I-NP
O	2473	2474	-	-	HYPH	I-NP
O	2474	2476	LH	LH	NN	I-NP
O	2476	2477	-	-	HYPH	I-NP
O	2477	2479	RH	RH	NN	I-NP
O	2480	2484	were	be	VBD	B-VP
O	2485	2493	compared	compare	VBN	I-VP
O	2494	2497	and	and	CC	O
O	2498	2508	contrasted	contrast	VBN	B-VP
O	2509	2513	with	with	IN	B-PP
O	2514	2519	those	those	DT	B-NP
O	2520	2528	produced	produce	VBN	B-VP
O	2529	2531	by	by	IN	B-PP
O	2532	2542	castration	castration	NN	B-NP
O	2542	2543	,	,	,	O
O	2544	2553	estrogens	estrogen	NNS	B-NP
O	2553	2554	,	,	,	O
O	2555	2568	antiandrogens	antiandrogen	NNS	B-NP
O	2568	2569	,	,	,	O
O	2570	2573	and	and	CC	O
O	2574	2586	progestogens	progestogen	NNS	B-NP
O	2586	2587	.	.	.	O
O	2587	2588	(	(	(	O
O	2588	2596	ABSTRACT	ABSTRACT	NN	B-NP
O	2597	2606	TRUNCATED	TRUNCATED	VBN	B-VP
O	2607	2609	AT	AT	IN	B-PP
O	2610	2613	400	400	CD	B-NP
O	2614	2619	WORDS	WORDS	NNS	I-NP
O	2619	2620	)	)	)	O

